Sam Kay

Sam Kay, CFA has had an extensive work experience in the pharmaceutical and biotechnology industry. Sam currently serves as the Executive Director of Business Development and Corporate Strategy at Mersana Therapeutics since December 2020. Prior to that, they were the Director of Business Development and Portfolio Strategy at Immunomedics from October 2018 to December 2020.

Sam also worked at Novartis, where they held multiple roles including Associate Director of US Oncology Strategy and Operations from January 2017 to October 2018, Associate Director of Oncology Global Business Analysis from August 2014 to December 2016, and Business Analyst in Market Intelligence from September 2011 to August 2014.

Earlier in their career, Sam worked at Labopharm as an Analyst in Market Intelligence from 2010 to 2011, and had an internship as an Investment Researcher at Aegis Capital LLC in 2010. Before that, they worked as a Project Manager and Market Intelligence Analyst at Akela Pharma from 2007 to 2009.

Sam Kay, CFA obtained a Bachelor of Science degree in Microbiology & Immunology and Neuroscience from McGill University in the period from 2004 to 2007. In 2014, they also obtained the Chartered Financial Analyst (CFA) certification from the CFA Institute.